Latest On AB Science S.A (ABSCF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-08-24 15:25 EST | News | AB Science's ALS drug Alsitek gets EMA review | N/A |  |
| 2021-07-22 16:25 EST | News | AB Science's masitinib extends survival in ALS significantly; shares rise 7% | N/A | |
| 2021-04-30 03:54 EST | News | AB Science's masitinib meets primary endpoint in prostate cancer study | N/A | |
| 2021-04-07 09:05 EST | News | AB Science licenses masitinib, other drugs to U of Chicago as potential COVID-19 therapies | N/A | |
| 2020-12-26 02:09 EST | News | AB Science's Masitinib: An Uncertain Success For Alzheimer's Disease | N/A | |
| 2020-12-18 23:52 EST | News | AB Science is rising after positive data from Alzheimer’s trial | N/A | |
| 2020-12-04 19:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-03 03:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 08:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 09:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-04 15:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 07:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 11:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 07:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 03:26 EST | Financials | Company financials have been released. | Neutral | |
About AB Science S.A (ABSCF):
AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.
General
- Name AB Science S.A
- Symbol ABSCF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 93
- Fiscal Year EndDecember
- Web URLhttp://www.ab-science.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 399.93
- Enterprise Value Revenue 527.69
View More
Financials
- Most Recent Quarter 2020-06-30
- Return on Assets -42%
- Earnings Per Share -$0.79
- Revenue Per Share $0
- Gross Profit 1.39 million
- Quarterly Earnings Growth 2%
View More
Highlights
- Market Capitalization 823.46 million
- Book Value Per Share -$0.01
View More
Share Statistics
- Shares Outstanding 44.35 million
- Shares Float 28.56 million
- % Held by Insiders 4361%
- % Held by Institutions 5.03%
View More
Technicals
- Beta 1.05
- 52 Week High $26.7
- 52 Week Low $6.9
- 50 Day Moving Average 19.35
- 200 Day Moving Average 19.75
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
AB Science S.A (ABSCF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
AB Science S.A (ABSCF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-06-30 | $N/A | -$0.13 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $N/A | -$0.13 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $N/A | -$0.12 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $395500 | -$0.12 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $395500 | -$0.19 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $414500 | -$0.19 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $414500 | -$0.23 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $436000 | -$0.23 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $436000 | -$0.17 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $448500 | -$0.18 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $448500 | -$0.23 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $421000 | -$0.23 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $421000 | -$0.21 | $0.00 | |
| 2016-12-31 | 2017-03-31 | -$0.20 | $0.00 | ||
| 2016-09-30 | 2016-12-31 | -$0.19 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | -$0.20 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$0.23 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.24 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.21 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$0.22 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.22 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.21 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.16 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.17 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$0.15 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.15 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.17 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.17 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.13 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.13 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$0.11 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.10 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.12 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.12 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.10 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.10 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$0.12 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.11 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.10 | $0.00 |
AB Science S.A (ABSCF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 4.8 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -6.51 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 824500 |
| Gross Profit | N/A | N/A | N/A | N/A | 335000 |
| Ebit | N/A | N/A | N/A | N/A | -5.29 million |
| Operating Income | N/A | N/A | N/A | N/A | -5.29 million |
| Income Tax Expense | 4000 | 4000 | N/A | N/A | 2000 |
| Total Revenue | N/A | N/A | N/A | N/A | 395500 |
| Cost of Revenue | N/A | N/A | N/A | N/A | 60500 |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -1.22 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -6.51 million |
| Net Income Applicable to Common Shares | -4.4 million | -4.4 million | -4.37 million | -4.37 million | -6.51 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -117000 | -117000 | -108000 | -108000 | -108500 |
| Net Borrowings | 2.73 million | 2.73 million | -1.1 million | -1.1 million | 1.1 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | 1.1 million |
| Change to Operating Activities | -601500 | -601500 | 1.11 million | 1.11 million | -347000 |
| Change in Cash | N/A | N/A | N/A | N/A | -4.42 million |
| Total Cash from Operating Activities | -3.85 million | -3.85 million | -2.17 million | -2.17 million | -5.41 million |
| Depreciation | N/A | N/A | N/A | N/A | 284000 |
| Other Cash Flow from Investing Activities | -31000 | -31000 | -15500 | -15500 | -20000 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 890000 | 890000 | 827000 | 827000 | 1.17 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | 88500 |
Balance Sheet:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 46.14 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | -27.93 million |
| Other Current Liabilities | 329000 | 329000 | N/A | N/A | 3.43 million |
| Total Assets | N/A | N/A | N/A | N/A | 18.21 million |
| Common Stock | 446000 | 446000 | 435000 | 435000 | 411000 |
| Other Current Assets | N/A | N/A | N/A | N/A | -1000 |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | 11 million | 11 million | 23.36 million | 23.36 million | 10.99 million |
| Other Assets | 65000 | 65000 | N/A | N/A | 1000 |
| Cash | N/A | N/A | N/A | N/A | 2.72 million |
| Total Current Liabilities | 24.08 million | 24.08 million | N/A | N/A | 23.33 million |
| Other Stockholder Equity | -238.82 million | -238.82 million | -230.16 million | -230.16 million | -221.61 million |
| Property, Plant & Equipment | 1.99 million | 1.99 million | 2.17 million | 2.17 million | 1.65 million |
| Total Current Assets | 19.12 million | 19.12 million | N/A | N/A | 14.92 million |
| Long Term Investments | N/A | N/A | N/A | N/A | 69000 |
| Net Tangible Assets | -29.65 million | -29.65 million | -28.25 million | -28.25 million | -29.5 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | 10.21 million |
| Inventory | 151000 | 151000 | N/A | N/A | 176000 |
| Accounts Payable | 14.35 million | 14.35 million | N/A | N/A | 16.58 million |
AB Science S.A (ABSCF) Chart:
AB Science S.A (ABSCF) News:
Below you will find a list of latest news for AB Science S.A (ABSCF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
AB Science S.A (ABSCF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
AB Science S.A (ABSCF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|